- Home
- XZO vs XERS Comparison
XZO vs XERS Comparison
Compare XZO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XZO | XERS |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XZO | XERS |
|---|---|---|
| Price | $14.64 | $9.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $26.00 | $12.29 |
| AVG Volume (30 Days) | 224.6K | ★ 1.9M |
| Earning Date | 11-15-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | 100.00 |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $216,980,000.00 | $49,590,000.00 |
| Revenue This Year | $2.01 | $32.77 |
| Revenue Next Year | $15.95 | $24.06 |
| P/E Ratio | $29.98 | ★ N/A |
| Revenue Growth | 61.99 | ★ 142.67 |
| 52 Week Low | $12.36 | $5.25 |
| 52 Week High | $24.60 | $10.09 |
Technical Indicators
Market Signals| Indicator | XZO | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 67.03 |
| Support Level | $12.84 | $7.15 |
| Resistance Level | $17.25 | N/A |
| Average True Range (ATR) | 0.70 | 0.46 |
| MACD | -0.21 | 0.18 |
| Stochastic Oscillator | 13.72 | 85.23 |
Price Performance
Historical ComparisonAbout XZO Exzeo Group Inc.
Exzeo Group Inc provides turnkey insurance technology and operations solutions to insurance carriers and their agents based on a proprietary platform of purpose-built software and data analytics applications that are specifically designed for the property and casualty, or P&C, insurance ecosystem. Its Insurance-as-a-Service (IaaS) platform, which it refers to as the Exzeo Platform, currently includes nine configurable software and data analytics applications that are purpose-built to serve insurance companies and other customers in the insurance value chain. Through the Exzeo Platform, the company provides technology-based solutions and services for all operational and administrative activities and functions needed by P&C insurance carriers and their agents.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.